Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ-1,99
KB0,90
PKN65,1165,142,13
Msft-0,17
Nokia3,29053,2965-1,02
IBM0,08
Mercedes-Benz Group AG73,8573,870,39
PFE-0,11
28.03.2024 23:35:52
Indexy online
AD Index online
select
AD Index online
 

  • 26.03.2024 14:10:26
Eli Lilly (LLY.S, Swiss Exchange)
Poslední obchod Změna (%) Změna (CHF) Objem obchodů (CHF)
690,00 0,73 5,00 69 000
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 28.03.2024
Popis společnosti
Obecné informace
Název společnostiEli Lilly And Co
TickerLLY
Kmenové akcie:Ordinary Shares
RICLLY
ISIN-
Poslední známé roční výsledky31.12.2023
Poslední známé čtvrtletní výsledky31.12.2023
Počet zaměstnanců k 31.12.2023 43 000
Akcie v oběhu k 16.02.2024 950 164 452
MěnaUSD
Konstituent indexůS&P 500
Kontaktní informace
UliceLilly Corporate Ctr
MěstoINDIANAPOLIS
PSČ46285-0001
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon13 172 762 000
Fax13172763492

Business Summary: Eli Lilly and Company is engaged in drug manufacturing businesses. The Company discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its diabetes, obesity and other cardiometabolic products include Basaglar, Humalog, Humulin, Jardiance, Mounjaro, Trulicity and Zepbound. Its oncology products include Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh and Taltz. Its neuroscience products include Cymbalta and Emgality. Its other products and therapies include Cialis and Forteo. The Company manufactures and distributes its products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Eli Lilly And Co revenues increased 20% to $34.12B. Net income decreased 16% to $5.24B. Revenues reflect Diabetes-Mounjaro segment increase from $482.5M to $5.16B, Oncology-Verzenio segment increase of 56% to $3.86B, U.S. segment increase of 20% to $21.79B, Europe segment increase of 44% to $6.17B. Net income was offset by Acquired in-Process Research and Deve increase from $908.5M to $3.8B (expense).
Odvětvová klasifikace
TRBC2012Pharmaceuticals (NEC)
RBSS2004Pharmaceuticals - Diversified
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICPharmaceutical Preparations
SICPharmaceutical Preparations
SICCommercial Physical Research



  • Poslední aktualizace: 28.03.2024
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Board, President, Chief Executive OfficerDavid Ricks5601.06.201701.01.2012
Chief Financial Officer, Executive Vice PresidentAnat Ashkenazi5009.02.2021
Executive Vice President, Chief Information and Digital OfficerDiogo Rau4817.05.2021
Executive Vice President - Enterprise Risk Management, Chief Ethics and Compliance OfficerAlonzo Weems5201.01.2021
Executive Vice President, General Counsel, SecretaryAnat Hakim53
Executive Vice President - Human Resources and DiversityEric Dozier5601.01.2022
Executive Vice President, President - Manufacturing OperationsEdgardo Hernandez4801.01.2021
Executive Vice President, President of Lilly Diabetes and Obesity and President of Lilly USAPatrik Jonsson5601.01.202431.08.2019
Executive Vice President - Global QualityJohna Norton56
Executive Vice President, Chief Executive Officer - Loxo Oncology at Lilly, President - Lilly OncologyJacob Van Naarden3805.09.2021